Condition: Lung Cancer · Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
This description comes directly from the study's public registry record.
Adam Schoenfeld, MD · 646-608-4042 · schoenfa@mskcc.org
Alexander Shoushtari, MD · 646-888-4161 · shoushta@mskcc.org
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering at Basking Ridge (Consent Only) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Consent Only) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Consent Only) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (Consent only) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All protocol activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center @ Nassau (Consent only) | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06863233